

Parietaria sublingual allergoid immunotherapy with a co-seasonal treatment schedule

R.W. D'Anneo^a, A. Arena^b, E. Gammeri^b, M.E. Bruno^c, P. Falagiani^c, G. Riva^c, S. Leonardi^d and M. La Rosa^d

^aRespiratory Centre Disease. Papardo Hospital. Messina. Italy. ^bRespiratory Centre Disease. ASL 5. Messina. Italy. ^cMedical Service. Lofarma S.p.A.. Milano. Italy. ^dPneumology Department. University. Catania. Italy.

ABSTRACT

Background: Sublingual immunotherapy (SLIT) with monomeric allergoid, given according to the standard scheme, resulted effective and safe. However, the achievement of a clinical benefit requires a long time. We thus performed this study using an administration protocol starting in the co-seasonal period with a 3-day build-up phase and lasting only 6 months, in order to obtain the above benefit in a shorter time.

Methods and results: The study, prospective, randomised and controlled versus drug therapy, was conducted on 65 rhinitic and/or asthmatic patients allergic to *Parietaria* with or without other sensitisations. Twenty-four were allocated to 1,000 AU/week, 21 to 3,000 AU/week and 21 to drug therapy. They were treated from April to September 2006. At baseline, 3 and 6 months a Visual Analogue Scale (VAS) was performed to assess the patients' well-being. Drug consumption was evaluated by means of monthly diary cards. Bronchial reactivity was investigated at baseline and 6 months by methacholine

challenge test. There was a greater VAS improvement in both the SLIT groups than in the controls after 6 months ($p < 0.05$). In patients taking 3,000 AU/week this was already evident after 3 months. There was a significant reduction in rescue medication consumption between 3 and 6 months ($p < 0.05$) in all three groups. The bronchial reactivity was reduced only in the SLIT groups ($p < 0.001$). No adverse events were observed.

Conclusions: At 6 months the allergoid SLIT showed itself to be effective and safe. In addition the subjective clinical benefit was obtained in a more rapid period, i.e. 3 instead of 6 months, when a higher maintenance dose was administered.

Key words: Asthma. Bronchial reactivity. Carbamylated allergoid. Methacholine. Sublingual immunotherapy. Rhinitis.

INTRODUCTION

Specific sublingual immunotherapy (SLIT) with monomeric allergoid (allergoid SLIT) has been shown to be clinically effective and safe in many clinical studies.¹⁻⁷ However, the standard induction build-up phase is rather time consuming, requiring from a minimum of 16 days (semi-rush schedule) to a maximum of 14 weeks (traditional schedule). In fact the build-up phase of SLIT has been designed according to the same criteria used for injective immunotherapy, where side effects are frequent, local and systemic, and in some rare cases severe and

Correspondence:

Dr. Marco E. Bruno
Medical Service
Lofarma S.p.A.
Viale Cassala, 40 - 20143 Milano, Italy
Tel.: + 39.02.581981
Fax: + 39.02.58198302
E-mail: lofscie@lofarma.it

even life-threatening. The safety profile of SLIT and, in particular, of the allergoid SLIT showed itself to be much higher compared to injective immunotherapy, and systemic and anaphylactic reactions are virtually absent, as documented by clinical trials and post-marketing surveillance studies.¹⁻⁷ We still do not know whether the use of higher dosages of the allergoid SLIT during the maintenance period can lead to faster effects and/or to an increase of its efficacy without compromising the good tolerability of the product.

The aims of the present study were therefore the following: 1) to evaluate the possibility of simplifying the initial build-up phase of the allergoid SLIT by shortening the induction phase to 3 days; 2) to verify if this therapy given in the co-seasonal period and lasting no more than 6 months, i.e. from April to September, can be effective and safe for *Parietaria* allergic patients; and finally, 3) to investigate if it is possible to increase the rapidity of effect and/or the efficacy of the allergoid SLIT even further, using a maintenance dosage higher than the standard one of 1,000 AU/week, i.e. 3,000 AU/week, yet maintaining the safety/tolerability profile of the lower dose.

It is noteworthy that *Parietaria* in the South of Italy has a very long pollination period, from March to September, with a peak from April to June. In Sicily, where the present study has been performed, *Parietaria* is practically a perennial allergen, with a pause in August (due to dryness), and another in December.

Table I
Patients' characteristics at baseline

	1,000 AU/week	3,000 AU/week	Control
Patients	24	21	21
Sex (M/F)	16/8	12/9	12/9
Mean age	26.3 ± 11.1	20.9 ± 8.8	27.9 ± 13.5
Weight	75.1 ± 40.0	58.6 ± 14.6	60.3 ± 13.2
Height	164.5 ± 13.9	162.8 ± 16.2	159.4 ± 13.8
Disease			
Asthma	6	6	7
Rhinitis and asthma	18	15	14
Allergen			
Parietaria	24	21	21
Dermatophagoides	18	15	16
Grass	3	–	2
Compositae	1	1	–
Olive	2	2	1
Dog	2	1	–
Cat	4	1	1
Birch	–	–	–
Alternaria	–	2	–
Aspergillus	–	1	–

MATERIALS AND METHODS

The study was prospective, randomized, with three parallel groups receiving either two different dosages of SLIT or the standard chronic pharmacotherapy, taken regularly, for rhinitis and/or mild persistent asthma. All three groups were allowed to receive rescue medication in addition to their assigned therapy in case of urgent need and, in any case, for a very short period (no more than three days).

No run-in period was scheduled. All patients were evaluated at entry to assess their baseline conditions. The parameters considered to evaluate the treatment efficacy were the Visual Analogue Scale (VAS) that was performed at baseline, after 3 months, and at the end of the study; the drug consumption that was measured during the whole study; and the assessment of the bronchial hyperactivity (BHR) by methacholine (MCh) test performed at baseline and at the end of the study.

Patients

Sixty-five patients suffering from rhinitis and/or mild persistent asthma and having never received any form of specific immunotherapy previously, have been enrolled. Patients' characteristics at baseline are described in Table I. Twenty-four patients (16M, 8F, mean age 26 ± 11 years) received the lower dose of the allergoid SLIT, 21 patients (12M, 9F, mean age 21 ± 8 years) the higher one and the remaining 21 (12M, 9F, mean age 28 ± 13 years) the standard chronic pharmacotherapy. All 65 patients were mainly sensitized to *Parietaria* as confirmed by a positive (> 3mm) skin prick test response (extracts Lofarma S.p.A., Milan, Italy) and positive CAP assay results (class II or greater) (CAP System EIA, Pharmacia, Uppsala, Sweden), and also, although to a lesser extent, to another allergen: House dust mite (n = 49), Grass (n = 5), Compositae (n = 2), Olive (n = 5), Dog epithelia (n = 3), Cat epithelia (n = 5), Birch pollen (n = 2), Alternaria (n = 2), Aspergillus (n = 1). Subjects suffering from systemic or immunological diseases, major anatomical alterations of the upper airways, renal insufficiency, coronary heart disease, neurologic or psychiatric diseases, receiving chronic corticosteroid or beta-blocking treatments were not admitted, nor were pregnant women. Finally, patients with mild BHR (defined as MCh PD₂₀ > 800 µg at baseline out of pollen season) were excluded from the study. All patients signed an informed consent before entering the study.

Investigational treatment

SLIT is a monomeric carbamylated allergoid (Lais[®], Lofarma S.p.A. Milan, Italy)⁸ biologically standardised in allergenic units (AU) and prepared as orosoluble tablets (allergoid SLIT). The tablets had to be taken in the morning on an empty stomach and kept under the tongue for 1-2 minutes until dissolution before swallowing. During the 3-day build-up phase, only the 1,000 AU tablets were used. The scheme was the following: 1 tablet the first day, 2 tablets the second day and 3 tablets the third day, for a total amount of 6,000 AU in three days. Subsequently, the patients have been treated either with a maintenance dosage of 1,000 AU/week (i.e. 1 tablet once a week) or 3,000 AU/week (i.e. 1 tablet 3 times a week) according to a computer-generated randomisation list. SLIT was administered continuously for 6 months. All the 65 SLIT patients were treated for *Parietaria* and for the other most relevant allergen (mainly house dust mite), whenever possible, using two different tablets. However, they were never treated for more than two allergens in any case.

The chronic standard pharmacological therapy consisted of antihistamines (cetirizine or loratadine tablets 10 mg, once daily) and long term intranasal steroids (fluticasone propionate, 125 µg, 2 sprays per nostril/die) in association with long acting bronchodilators (salmeterol, 100 µg/die) for patients with asthmatic symptoms as well.

The rescue medication, to be administered for symptom control, only in the event of urgent need and for no more than three days, was the following in all three groups: cetirizine or loratadine tablets 10 mg, two or more tablets/day, inhaled salbutamol 100 µg, 2-3 puffs or more/die, intranasal fluticasone propionate 250 µg, 2 or more sprays per nostril/die and beclometasone tablets 1 mg, 1 tablet once or twice daily.

Clinical evaluation

Patients were required to fill in a specific graduated scale called Visual Analogue Scale (VAS) which explores the degree of patient well-being and thus, indirectly, the severity of his/her symptoms during the last six or three months. In our study the maximum level of well-being was 10 and the minimum was 0. The VAS had to be filled in at entry, and after 3 and 6 months. The consumption of the rescue medications was scored 1 point if no drug was consumed in that month, 2 points if the consumption was scarce (i.e. no more than 5 days with the need of a rescue therapy in that month), 3 if this was in the av-

erage (i.e. no more than 10 days with the need of a rescue therapy in that month) and 4 if this was elevated, regardless of the kind of drug (i.e. more than 10 days with the need of a rescue therapy in that month). Then, at 3 and 6 months, a cumulative drug intake score was calculated, each kind of drug being scored separately and differently from the others, with systemic steroids having the highest score.

All patients were also required to record on a separate diary any untoward effect. As far as the allergoid SLIT is concerned, adverse events (AE) were subdivided into local AE (oral itching, swelling of tongue) and systemic (asthma, rhinitis, urticaria, abdominal pain/diarrhoea, anaphylaxis).

Methacholine challenge

MCh bronchial provocation test was performed using an ampoule-dosimeter (Mefar Elettromedicali, Brescia, Italy). An inspiratory effort for 0.5s activated a solenoid valve, delivering 5 µL of solution. Lyophilized MCh chloride (Lofarma S.p.A, Milan, Italy) was reconstituted, to obtain 0.2 % and 1.0 % concentrations. After saline control, MCh was administered in double increasing amounts: each subject inhaled 1 and 2 breaths of 0.2 % MCh solution (each breath corresponding to 10 µg of MCh), followed by 1, 2, 4, 8, 16, and again 16 breaths of 1.0 % solution (each corresponding to 50 µg of MCh). FEV₁ was recorded about 2 minutes after each MCh dose. All bronchial challenges were performed at the same time of the day under the same environmental conditions. The MCh test was done out of the pollen season both at entry and at the study end. The cumulative administered dose of MCh causing a reduction of 20 % of the baseline FEV₁ (PD₂₀) was computed by interpolating the MCh cumulative doses immediately preceding and following the 20 % fall of FEV₁.

Degree of BHR

Three arbitrary classes of BHR were considered: mild = PD₂₀ > 800 µg/ml (in this case the patient was not included in the study), mild-moderate = PD₂₀ ranging from 400 to 800 µg/ml and moderate-severe = PD₂₀ < 400 µg/ml (9).

Statistical analysis

To evaluate the changes of VAS, MCh and symptom score in comparison to the baseline values the

Wilcoxon Signed Ranks Test was used. To determine whether the values of a particular variable differ among the three populations (1,000 AU vs 3,000 AU vs control), the Mann-Whitney test for intergroup comparison was used. P values less than 0.05 were considered significant.

RESULTS

Build-up phase, drop-outs and safety

All the patients tolerated both the 3-day induction build-up phase and the 6-month maintenance thera-

py very well. Furthermore no patient interrupted the study because of adverse events.

VAS

The VAS results are described in Figure 1. At baseline there were no significant differences among the three groups. A significant increase of VAS values has been observed in all the three study groups in comparison to baseline ($p < 0.001$). Considering the three different groups, it is worth noting that, after 6 months, the scores obtained with both the SLIT dosages are statistically better than those observed in the controls ($p < 0.05$) while, at the 3rd month, only that obtained with the higher dose was statistically superior to the control ($p < 0.05$).

Drug consumption

During the last 3 months there was a statistically significant reduction in the consumption of the rescue medication (mainly antihistamines and bronchodilators) in comparison to the first 3 months, in both the 1,000 AU and the control group ($p < 0.05$). However, in those patients treated with the higher SLIT dose that did not happen, probably because the rescue drug consumption was already very low during the first three months, i.e. during the peak of the pollen season, probably because of the very rapid action of this dosage. Besides, comparing the 3 groups at the 3rd month of therapy, the 3,000 AU dosage was the only one that showed a reduction in rescue medication consumption in comparison to the control group ($p < 0.05$) while there was not any statistical difference between the results of the two SLIT groups (Fig. 2).




Figure 1.—VAS mean values at baseline, after 3 and 6 months treatment in the 3 groups of patients.




Figure 2.—Drug consumption during the study in the three groups of patients.




Figure 3.—Methacholine PD₂₀ mean values (μg) at baseline and after 6 months treatment in the 3 groups of patients.

Methacholine challenge

A significant increase of MCh PD₂₀ was observed, at the end of the study, in comparison to the baseline values, in both the patients treated with 1,000 AU ($p < 0.05$) and in those treated with 3,000 AU ($p < 0.001$). It has to be noted that, in the patients assigned to the higher dosage, the PD₂₀ values were a bit lower both at baseline and after 6 months, without reaching statistical significance. Neither clinical nor statistical differences were observed in the patients treated only with drugs (Fig. 3).

DISCUSSION

The schedule used for the induction build-up phase in the present study has two peculiarities: the shortness of the up-dosing phase, 3 days, and the fact that the initial dose was quite high i.e. a tablet containing 1,000 AU, corresponding to the lower maintenance dose per week. That allows the handling of a unique type of tablet titrated at 1,000 AU, then consistently simplifying the treatment and preventing mistakes in dosages. Moreover, with the present schedule the maintenance phase can begin much earlier, with a possible consistent advantage as regards the quickness in reaching a clinical benefit. The schedule employed in the present study consists in administering a cumulative dose of 6,000 AU in 3 days, slightly higher than that (4,000 AU) employed by Rossi & Monasterolo in their ultra-rush up-dosing study, where the administration of all the dosages lasted only 20 minutes.⁴ In both studies the administration of such high dosages in a short time did not determine the appearance of relevant adverse reactions. Similar results were obtained in the study of Gammeri et al.¹⁰ On the whole, these data confirm the good tolerability and safety of the allergoid SLIT, even if administered in a very short time. That is probably ascribable to the low IgE-binding activity of the active principle⁸ which prevents the IgE-mediated allergen presentation by dendritic cells to T_H2 cells, which is the key-mechanism to explain the strong increase of allergen-specific IgE observed in the course of SLIT with native grass allergens.¹¹ On the contrary, in the course of SLIT with Dermatophagoides carabamylated allergoid a progressive decrease of allergen-specific IgE was observed.¹²

As regards the efficacy, a correlation can be noted between the SLIT dose, the clinical effects and time, i.e. both the SLIT doses were shown to be more effective than the controls at the 6th month as far as

the VAS and the MCh challenge were concerned, without any difference between them but, on the other hand, when the 3rd month is considered, a significantly greater improvement of the VAS score and a significant reduction of drug consumption in comparison to the controls was observed only with the 3,000 AU dose. This, to our opinion, could be a possible demonstration of the greater rapidity of effect of the higher dosage in comparison to the lower one.

A dose-response effect concerning SLIT effectiveness has in fact been previously described also by other authors.¹³ Yet, in this case, more than the absolute efficacy, it is the rapidity of effect obtainable by increasing the frequency of administration in a certain period of time that emerges from our data. This time-response effect was also observed by Di Gioacchino et al. in an immunological study comparing the effects on IL-10 and other cytokines (INF- γ , IL-4, IL-6, IL-2, TNF- α) of two different SLIT induction schemes, one lasting 14 weeks and the other 16 days. It emerged that the faster way of administration, with the consumption of the tablets closer one to the other, was associated with a greater movement of the above parameters regardless of the total amount of allergen administered.

In our study the speed of administration during the build-up phase was the same in the two groups, so this was not able to influence the results between the two SLIT groups, while the total dosage of allergen and the frequency of administration were different. In the light of these study limitations, at the moment we can state that: 1) to obtain a clinical benefit in a more rapid period, i.e. 3 months instead of, for example, 6 months, we can act on two different factors: the total dosage of allergen administered and the frequency of its administration; 2) after a longer period of time, 6 months or more, no significant difference between the clinical effects of the two administration schemes (1 tablet once a week vs 1 tablet three times a week) was observed.

Considering that the maximum pollination period for *Parietaria* in Southern Italy ranges from April to June¹⁴ (Fig. 4) which corresponds with the worsening of the allergic symptoms in most patients, we can speculate that a maintenance dosage based on the administration of 3,000 AU started immediately before the beginning of the maximum pollination period, followed by a further three months of treatment with 1,000 AU once a week, could be useful to obtain a more rapid and prolonged clinical benefit without any remarkable adverse reaction in neither the short nor the long term.




Figure 4.—Data on the *Urticaceae* pollen season in Southern Italy during 2006.

REFERENCES

1. Passalacqua G, Albano M, Fregonese L, Riccio A, Pronzato C, Mela GS et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. *Lancet* 1998;351:629-32.
2. Lombardi C, Gargioni S, Melchiorre A, Tiri A, Falagiani P, Canonica GW et al. Safety of sublingual immunotherapy with monomeric allergoid in adults: multicenter post-marketing surveillance study. *Allergy* 2001;56:989-92.
3. Di Rienzo V, Pagani A, Parmiani S, Passalacqua G, Canonica GW. Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients. *Allergy* 1999; 54:1110-3.
4. Rossi RE, Monasterolo G. A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma. *Int J Immunopathol Pharmacol* 2005;18:277-85.
5. Grosclaude M, Bouillot P, Alt R, Leynadier F, Scheinmann P, Ruffin P et al. Safety of various dosage regimens during induction of sublingual immunotherapy. A preliminary study. *Int Arch Allergy Immunol* 2002;129:248-53.
6. Passalacqua G, Lombardi C, Guerra L, Compalati E, Fumagalli F, Canonica GW. Sublingual immunotherapy: no more doubts. *Eur Ann Allergy Clin Immunol* 2005;37:314-20.
7. Giordano T, Quarta C, Bruno ME, Falagiani P, Riva G. Safety, tolerability and efficacy of sublingual allergoid immunotherapy with a 4-day shortened build-up phase. *Eur Ann Allergy Clin Immunol* 2006;9:310-2.
8. Mistrello G, Brenna O, Roncarolo D, Zanoni D, Gentili M, Falagiani P. Monomeric chemically modified allergens: immunologic and physicochemical characterization. *Allergy* 1996; 51:8-15.
9. La Grutta S, Arena A, D'Anneo WR, Gammeri E, Leonardi S, Trimarchi A, et al. Evaluation of the antiinflammatory and clinical effects of sublingual immunotherapy with carbamylated allergoid in allergic asthma with or without rhinitis. A 12-month perspective randomized, controlled trial. *Eur Ann Allergy Clin Immunol* 2007; 39:40-4.
10. Gammeri E, Arena A, D'Anneo R, La Grutta S. Safety and tolerability of ultra-rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma. *Allergol Immunopathol* 2005;33:142-4.
11. Durham SR, Yang WH, Pedersen MR, Johansen N, Eng Msc-C, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. *J Allergy Clin Immunol* 2006; 117:802-9.
12. Cosmi L, Santarlasci V, Angeli R, Liotta F, Maggi L, Frosali F et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon- γ - and interleukin-10-production. *Clin Exp Allergy* 2006;36:261-72.
13. Calderon M, Essendrop M. Specific immunotherapy with high dose SQ standardized grass allergen tablets was safe and well tolerated. *J Invest Clin Immunol* 2006;16:338-44.
14. Capperucci C, De Nuntiis P. La rete di monitoraggio nel 2006 tradizione e nuove prospettive. *Not Allergol* 2006;25:83-8.